ParkinsonFranceV1, PascalFrancis, Corpus, bibRecord, 001802

Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease

Identifieur interne : 001802 ( PascalFrancis/Corpus ); précédent : 001801; suivant : 001803

Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease

Auteurs : A. F. Carpentier ; A. M. Bonnet ; M. Vidailhet ; Y. Agid

Source :

Neurology [ 0028-3878 ] ; 1996.

RBID : Pascal:96-0309011

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Dyskinésie, Lévodopa, Antiparkinsonien, Propranolol, Bloquant β-adrénergique, Antagoniste, Traitement, Homme, Récepteur β-adrénergique, Chimiothérapie, Dose faible, Traitement adjuvant.

English descriptors

KwdEn :
- Adjuvant treatment, Antagonist, Antiparkinson agent, Beta blocking agent, Chemotherapy, Dyskinesia, Human, Levodopa, Low dose, Parkinson disease, Treatment, β-Adrenergic receptor.

Abstract

Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment. There was a significant 40% improvement in the dyskinesia score without increase of parkinsonian motor disability. Ballistic and choreic dyskinesia were markedly ameliorated, whereas dystonia was not. This study suggests that administration of low doses of beta-blockers may improve levodopa-induced ballistic and choreic dyskinesia in PD.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0028-3878`
A02	`01`			`@0 NEURAI`
A03		`1`		`@0 Neurology`
A05				`@2 46`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease`
A11	`01`	`1`		`@1 CARPENTIER (A. F.)`
A11	`02`	`1`		`@1 BONNET (A. M.)`
A11	`03`	`1`		`@1 VIDAILHET (M.)`
A11	`04`	`1`		`@1 AGID (Y.)`
A14	`01`			`@1 Fédération de Neurologie and INSERM U289, Hôpital de la Salpétrière @2 Paris @3 FRA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut.`
A20				`@1 1548-1551`
A21				`@1 1996`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 6345 @5 354000044116590100`
A44				`@0 0000 @1 © 1996 INIST-CNRS. All rights reserved.`
A45				`@0 13 ref.`
A47	`01`	`1`		`@0 96-0309011`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Neurology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment. There was a significant 40% improvement in the dyskinesia score without increase of parkinsonian motor disability. Ballistic and choreic dyskinesia were markedly ameliorated, whereas dystonia was not. This study suggests that administration of low doses of beta-blockers may improve levodopa-induced ballistic and choreic dyskinesia in PD.
C02	`01`	`X`		`@0 002B02F05`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Dyskinésie @5 04`
C03	`02`	`X`	`ENG`	`@0 Dyskinesia @5 04`
C03	`02`	`X`	`SPA`	`@0 Disquinesia @5 04`
C03	`03`	`X`	`FRE`	`@0 Lévodopa @5 07`
C03	`03`	`X`	`ENG`	`@0 Levodopa @5 07`
C03	`03`	`X`	`SPA`	`@0 Levodopa @5 07`
C03	`04`	`X`	`FRE`	`@0 Antiparkinsonien @5 08`
C03	`04`	`X`	`ENG`	`@0 Antiparkinson agent @5 08`
C03	`04`	`X`	`SPA`	`@0 Antiparkinsoniano @5 08`
C03	`05`	`X`	`FRE`	`@0 Propranolol @2 NK @2 FR @5 10`
C03	`06`	`X`	`FRE`	`@0 Bloquant β-adrénergique @5 11`
C03	`06`	`X`	`ENG`	`@0 Beta blocking agent @5 11`
C03	`06`	`X`	`SPA`	`@0 Bloqueador β-adrenérgico @5 11`
C03	`07`	`X`	`FRE`	`@0 Antagoniste @5 16`
C03	`07`	`X`	`ENG`	`@0 Antagonist @5 16`
C03	`07`	`X`	`SPA`	`@0 Antagonista @5 16`
C03	`08`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`08`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`08`	`X`	`GER`	`@0 Aufbereiten @5 17`
C03	`08`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`09`	`X`	`FRE`	`@0 Homme @5 20`
C03	`09`	`X`	`ENG`	`@0 Human @5 20`
C03	`09`	`X`	`SPA`	`@0 Hombre @5 20`
C03	`10`	`X`	`FRE`	`@0 Récepteur β-adrénergique @5 23`
C03	`10`	`X`	`ENG`	`@0 β-Adrenergic receptor @5 23 @6 «β-»Adrenergic receptor`
C03	`10`	`X`	`SPA`	`@0 Receptor β-adrenérgico @5 23`
C03	`11`	`X`	`FRE`	`@0 Chimiothérapie @5 24`
C03	`11`	`X`	`ENG`	`@0 Chemotherapy @5 24`
C03	`11`	`X`	`SPA`	`@0 Quimioterapia @5 24`
C03	`12`	`X`	`FRE`	`@0 Dose faible @5 35`
C03	`12`	`X`	`ENG`	`@0 Low dose @5 35`
C03	`12`	`X`	`SPA`	`@0 Dosis débil @5 35`
C03	`13`	`X`	`FRE`	`@0 Traitement adjuvant @5 36`
C03	`13`	`X`	`ENG`	`@0 Adjuvant treatment @5 36`
C03	`13`	`X`	`SPA`	`@0 Tratamiento adyuvante @5 36`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`06`	`X`	`FRE`	`@0 Trouble neurologique @5 46`
C07	`06`	`X`	`ENG`	`@0 Neurological disorder @5 46`
C07	`06`	`X`	`SPA`	`@0 Trastorno neurológico @5 46`
C07	`07`	`X`	`FRE`	`@0 Mouvement involontaire @5 47`
C07	`07`	`X`	`ENG`	`@0 Involuntary movement @5 47`
C07	`07`	`X`	`SPA`	`@0 Movimiento involuntario @5 47`
N21				`@1 211`

Format Inist (serveur)

NO :	PASCAL 96-0309011 INIST
ET :	Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease
AU :	CARPENTIER (A. F.); BONNET (A. M.); VIDAILHET (M.); AGID (Y.)
AF :	Fédération de Neurologie and INSERM U289, Hôpital de la Salpétrière/Paris/France (1 aut., 2 aut., 3 aut., 4 aut.)
DT :	Publication en série; Niveau analytique
SO :	Neurology; ISSN 0028-3878; Coden NEURAI; Etats-Unis; Da. 1996; Vol. 46; No. 6; Pp. 1548-1551; Bibl. 13 ref.
LA :	Anglais
EA :	Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment. There was a significant 40% improvement in the dyskinesia score without increase of parkinsonian motor disability. Ballistic and choreic dyskinesia were markedly ameliorated, whereas dystonia was not. This study suggests that administration of low doses of beta-blockers may improve levodopa-induced ballistic and choreic dyskinesia in PD.
CC :	002B02F05
FD :	Parkinson maladie; Dyskinésie; Lévodopa; Antiparkinsonien; Propranolol; Bloquant β-adrénergique; Antagoniste; Traitement; Homme; Récepteur β-adrénergique; Chimiothérapie; Dose faible; Traitement adjuvant
FG :	Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Trouble neurologique; Mouvement involontaire
ED :	Parkinson disease; Dyskinesia; Levodopa; Antiparkinson agent; Beta blocking agent; Antagonist; Treatment; Human; β-Adrenergic receptor; Chemotherapy; Low dose; Adjuvant treatment
EG :	Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Neurological disorder; Involuntary movement
GD :	Aufbereiten
SD :	Parkinson enfermedad; Disquinesia; Levodopa; Antiparkinsoniano; Bloqueador β-adrenérgico; Antagonista; Tratamiento; Hombre; Receptor β-adrenérgico; Quimioterapia; Dosis débil; Tratamiento adyuvante
LO :	INIST-6345.354000044116590100
ID :	96-0309011

Links to Exploration step

Pascal:96-0309011

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease</title>
<author><name sortKey="Carpentier, A F" sort="Carpentier, A F" uniqKey="Carpentier A" first="A. F." last="Carpentier">A. F. Carpentier</name>
<affiliation><inist:fA14 i1="01"><s1>Fédération de Neurologie and INSERM U289, Hôpital de la Salpétrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bonnet, A M" sort="Bonnet, A M" uniqKey="Bonnet A" first="A. M." last="Bonnet">A. M. Bonnet</name>
<affiliation><inist:fA14 i1="01"><s1>Fédération de Neurologie and INSERM U289, Hôpital de la Salpétrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Vidailhet, M" sort="Vidailhet, M" uniqKey="Vidailhet M" first="M." last="Vidailhet">M. Vidailhet</name>
<affiliation><inist:fA14 i1="01"><s1>Fédération de Neurologie and INSERM U289, Hôpital de la Salpétrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Y. Agid</name>
<affiliation><inist:fA14 i1="01"><s1>Fédération de Neurologie and INSERM U289, Hôpital de la Salpétrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">96-0309011</idno>
<date when="1996">1996</date>
<idno type="stanalyst">PASCAL 96-0309011 INIST</idno>
<idno type="RBID">Pascal:96-0309011</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001802</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease</title>
<author><name sortKey="Carpentier, A F" sort="Carpentier, A F" uniqKey="Carpentier A" first="A. F." last="Carpentier">A. F. Carpentier</name>
<affiliation><inist:fA14 i1="01"><s1>Fédération de Neurologie and INSERM U289, Hôpital de la Salpétrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bonnet, A M" sort="Bonnet, A M" uniqKey="Bonnet A" first="A. M." last="Bonnet">A. M. Bonnet</name>
<affiliation><inist:fA14 i1="01"><s1>Fédération de Neurologie and INSERM U289, Hôpital de la Salpétrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Vidailhet, M" sort="Vidailhet, M" uniqKey="Vidailhet M" first="M." last="Vidailhet">M. Vidailhet</name>
<affiliation><inist:fA14 i1="01"><s1>Fédération de Neurologie and INSERM U289, Hôpital de la Salpétrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Y. Agid</name>
<affiliation><inist:fA14 i1="01"><s1>Fédération de Neurologie and INSERM U289, Hôpital de la Salpétrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
<imprint><date when="1996">1996</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvant treatment</term>
<term>Antagonist</term>
<term>Antiparkinson agent</term>
<term>Beta blocking agent</term>
<term>Chemotherapy</term>
<term>Dyskinesia</term>
<term>Human</term>
<term>Levodopa</term>
<term>Low dose</term>
<term>Parkinson disease</term>
<term>Treatment</term>
<term>β-Adrenergic receptor</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Dyskinésie</term>
<term>Lévodopa</term>
<term>Antiparkinsonien</term>
<term>Propranolol</term>
<term>Bloquant β-adrénergique</term>
<term>Antagoniste</term>
<term>Traitement</term>
<term>Homme</term>
<term>Récepteur β-adrénergique</term>
<term>Chimiothérapie</term>
<term>Dose faible</term>
<term>Traitement adjuvant</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment. There was a significant 40% improvement in the dyskinesia score without increase of parkinsonian motor disability. Ballistic and choreic dyskinesia were markedly ameliorated, whereas dystonia was not. This study suggests that administration of low doses of beta-blockers may improve levodopa-induced ballistic and choreic dyskinesia in PD.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0028-3878</s0>
</fA01>
<fA02 i1="01"><s0>NEURAI</s0>
</fA02>
<fA03 i2="1"><s0>Neurology</s0>
</fA03>
<fA05><s2>46</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>CARPENTIER (A. F.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BONNET (A. M.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>VIDAILHET (M.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>AGID (Y.)</s1>
</fA11>
<fA14 i1="01"><s1>Fédération de Neurologie and INSERM U289, Hôpital de la Salpétrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>1548-1551</s1>
</fA20>
<fA21><s1>1996</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>6345</s2>
<s5>354000044116590100</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1996 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>13 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>96-0309011</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Neurology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment. There was a significant 40% improvement in the dyskinesia score without increase of parkinsonian motor disability. Ballistic and choreic dyskinesia were markedly ameliorated, whereas dystonia was not. This study suggests that administration of low doses of beta-blockers may improve levodopa-induced ballistic and choreic dyskinesia in PD.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02F05</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Lévodopa</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Levodopa</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Levodopa</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Propranolol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Bloquant β-adrénergique</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Beta blocking agent</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Bloqueador β-adrenérgico</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Antagoniste</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Antagonist</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Antagonista</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="GER"><s0>Aufbereiten</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Récepteur β-adrénergique</s0>
<s5>23</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>β-Adrenergic receptor</s0>
<s5>23</s5>
<s6>«β-»Adrenergic receptor</s6>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Receptor β-adrenérgico</s0>
<s5>23</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>24</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>24</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>24</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Dose faible</s0>
<s5>35</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Low dose</s0>
<s5>35</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Dosis débil</s0>
<s5>35</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Traitement adjuvant</s0>
<s5>36</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Adjuvant treatment</s0>
<s5>36</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Tratamiento adyuvante</s0>
<s5>36</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>46</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>46</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>46</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>47</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>47</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>47</s5>
</fC07>
<fN21><s1>211</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 96-0309011 INIST</NO>
<ET>Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease</ET>
<AU>CARPENTIER (A. F.); BONNET (A. M.); VIDAILHET (M.); AGID (Y.)</AU>
<AF>Fédération de Neurologie and INSERM U289, Hôpital de la Salpétrière/Paris/France (1 aut., 2 aut., 3 aut., 4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Neurology; ISSN 0028-3878; Coden NEURAI; Etats-Unis; Da. 1996; Vol. 46; No. 6; Pp. 1548-1551; Bibl. 13 ref.</SO>
<LA>Anglais</LA>
<EA>Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment. There was a significant 40% improvement in the dyskinesia score without increase of parkinsonian motor disability. Ballistic and choreic dyskinesia were markedly ameliorated, whereas dystonia was not. This study suggests that administration of low doses of beta-blockers may improve levodopa-induced ballistic and choreic dyskinesia in PD.</EA>
<CC>002B02F05</CC>
<FD>Parkinson maladie; Dyskinésie; Lévodopa; Antiparkinsonien; Propranolol; Bloquant β-adrénergique; Antagoniste; Traitement; Homme; Récepteur β-adrénergique; Chimiothérapie; Dose faible; Traitement adjuvant</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Trouble neurologique; Mouvement involontaire</FG>
<ED>Parkinson disease; Dyskinesia; Levodopa; Antiparkinson agent; Beta blocking agent; Antagonist; Treatment; Human; β-Adrenergic receptor; Chemotherapy; Low dose; Adjuvant treatment</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Neurological disorder; Involuntary movement</EG>
<GD>Aufbereiten</GD>
<SD>Parkinson enfermedad; Disquinesia; Levodopa; Antiparkinsoniano; Bloqueador β-adrenérgico; Antagonista; Tratamiento; Hombre; Receptor β-adrenérgico; Quimioterapia; Dosis débil; Tratamiento adyuvante</SD>
<LO>INIST-6345.354000044116590100</LO>
<ID>96-0309011</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001802 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001802 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:96-0309011
   |texte=   Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease

Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri